Press releases

May 24, 2023

Ultragenyx Issues 2022 Environmental, Social and Governance (ESG) Report

Read more

May 19, 2023

Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit

Read more

May 18, 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

May 17, 2023

Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.

Read more

May 08, 2023

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting

Read more

May 05, 2023

Ultragenyx to Present at Bank of America’s 2023 Health Care Conference

Read more

May 04, 2023

Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update

Read more

April 27, 2023

Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update

Read more

April 19, 2023

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

March 28, 2023

Ultragenyx to Present at Guggenheim’s Genomic Medicines and Rare Disease Days

Read more